Figures
Citation: Crisan CV, Goldberg JB (2025) Stenotrophomonas maltophilia complex: A broadly distributed emerging pathogen. PLoS Pathog 21(8): e1013422. https://doi.org/10.1371/journal.ppat.1013422
Editor: John M. Leong, Tufts Univ School of Medicine, UNITED STATES OF AMERICA
Published: August 21, 2025
Copyright: © 2025 Crisan, Goldberg. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: CVC was supported by the Cystic Fibrosis Foundation grants CRISAN22F0 and CRISAN25F0. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
What is Stenotrophomonas maltophilia complex?
Stenotrophomonas maltophilia complex (Smc) is a group of globally distributed gram-negative Gammaproteobacteria from the Lysobacterales order that colonize soil, water, and plant ecosystems [1]. In addition to these natural environments, Smc strains are found in anthropogenic settings like hospitals, especially in intensive care units, and other healthcare facilities [1,2]. Isolates exhibit a high level of genomic diversity and have been classified into 23 monophyletic lineages [1]. Sm6, also known as S. maltophilia sensu stricto, is the most common lineage [1]. K279a (isolated from the blood of a cancer patient) belongs to the Sm6 lineage and is one of the best characterized Smc strains [3]. Lineages that are more closely related to Sm6 (Sm1-Sm5 and Sm7-Sm18) are classified as S. maltophilia sensu lato, while Sgn1–4 (Stenotrophomonas genospecies 1–4) are the most distantly related to Sm6 [1]. Multiple lineages, including Sm2, Sm4a, Sm4b, Sm6, and Sm13 are associated with human infections, while Sgn1–3 are primarily recovered from environmental sources [1].
Why is Smc clinically important?
Many Smc isolates are opportunistic pathogens that can infect the lungs, brain, skin, urinary tract, eyes, and blood [4–8]. Due to this bacterium’s ability to contaminate and colonize medical equipment and other healthcare surfaces, nosocomial infections are a significant concern (Fig 1) [9]. Blood infections are especially dangerous and can have mortality rates above 65%; in a study with over 1600 bacteremia patients, Smc was the most frequently detected carbapenem-resistant gram-negative pathogen [5,10]. Bacteria from this group can cause serious health problems for people with cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD), COVID-19, or cancer [4,9,11,12]. CF and COPD patients that acquire Smc infections are more likely to suffer from worse health outcomes, have higher mortality, and lower pulmonary functions [11,12]. Smc isolates had the highest rates of multidrug resistance among bacterial pathogens that infect COVID-19 patients [4]. Multiple risk factors, including mechanical ventilation, venous catheters, tracheotomies, and previous exposure to antibiotics can contribute to Smc infections [2,13,14]. Because people with weakened immune systems or other underlying conditions are the most vulnerable, some debate exists whether this bacterium is a true pathogen or if its detection represents a marker for severe disease.
The ability of Smc bacteria to survive in polymicrobial communities, to colonize natural environments like soil and water, and to contaminate surfaces in healthcare settings may contribute to the potential to infect susceptible people and cause disease. Images used to build this figure are freely available and can be modified or adapted under the National Institutes of Health NIH BIOART Source Public Domain License (https://bioart.niaid.nih.gov/bioart/42, https://bioart.niaid.nih.gov/bioart/206, and https://bioart.niaid.nih.gov/bioart/519), Open Clipart Public Domain License, (https://openclipart.org/detail/62785/virus), and Pixabay Content License (https://pixabay.com/vectors/ground-nature-plant-spring-2022491/).
Importantly, the number of Smc infections has been increasing in the last decades [15,16]. This phenomenon could be explained by a higher number of admissions to critical care units and increasing rates of underlying conditions like cancer [17,18]. Furthermore, improved detection procedures that classify clinical isolates with better accuracy and a greater recognition about the pathogenic potential of Smc among clinicians could also be responsible for the reported increased infection rates [19,20].
Multiple factors contribute to this bacterium’s ability to adhere to surfaces (Fig 2). Biofilms are dense microbial communities that consist of cells encased in a complex matrix composed of polysaccharides, DNA, lipids, and/or proteins [21]. This matrix enhances bacterial adhesion to abiotic surfaces and eukaryotic cells. Most Smc isolates can form biofilms, but the amount of secreted extracellular matrix is variable and strain-dependent [21]. Polar flagella, which are tail-like macromolecular structures involved in motility and adhesion, are present on the surface of Smc cells and modulate host immune responses [22]. Hair-like projections distributed on the membrane (called fimbriae) also enhance the ability of this pathogen to adhere to surfaces [23].
Secreted biofilm products facilitate adherence to abiotic surfaces and eukaryotic cells, while membrane appendages like flagella and pili contribute to motility and adherence. Protein secretion systems export virulence factors and antibacterial proteins. Smc antibiotic efflux pumps and β-lactamases confer resistance to antibiotics, while putative defense systems may prevent phage infections. Siderophores and transport proteins allow iron to be transported into cells. The image used to build this figure is freely available and can be modified or adapted under the National Institutes of Health NIH BIOART Source Public Domain license (https://bioart.niaid.nih.gov/bioart/42).
Secreted proteins play important roles in Smc virulence. The Type II Secretion System (T2SS) is used by many pathogens to excrete proteinaceous virulence factors [24,25]. This macromolecular apparatus spans the inner membrane, periplasm, and outer membrane of gram-negative bacteria and translocates bacterial toxins to the extracellular milieu in an ATP-dependent manner [24,25]. Strain K279a exports multiple T2SS proteases that induce host cellular damage, degrade eukaryotic proteins, and modulate immune system responses [24,25]. StmPr1 is a T2SS serine protease that degrades cellular adherens and tight junctions, contributes to cell death, and induces interleukin-8 (IL-8) secretion through the protease-activated receptor 2 [25,26]. StmPr1 is the main T2SS virulence factor in K279a and is encoded by the majority of Smc strains from all lineages [1,25]. StmPr2 and StmPr3 are additional T2SS proteases secreted by K279a that degrade eukaryotic proteins and induce cellular toxicity [25,26]. StmPr1, StmPr2, and StmPr3 share sequence homology to proteases encoded by bacteria from the Xanthomonas genus [25,26].
K279a also encodes a functional Type IV Secretion System (T4SS) that is structurally and functionally distinct from the T2SS [27]. The T4SS assembles a large proteinaceous nanomachine that consists of an inner membrane complex connected to an outer membrane complex through a periplasmic stalk-like structure [27]. Bacterial processes like conjugation, natural transformation, and virulence factor export are mediated by the T4SS. In K279a, the T4SS apparatus induces apoptosis in macrophage cells while reducing apoptosis in human alveolar adenocarcinoma cells [27]. Although it is unclear which effector proteins are responsible for the ability of K279a to regulate eukaryotic cell death, T4SS-mediated apoptotic modulation is caspase-dependent [27].
Other secreted small molecules and protein complexes can contribute to virulence in Smc bacteria. Iron serves as a cofactor for enzymes that catalyze core metabolic reactions and is an essential nutrient that most bacterial pathogens acquire from hosts during infections [28]. Sm6 strain K279a produces siderophores and efflux pumps that maintain iron homeostasis [28]. Iron also serves as an external signal that alters expression of virulence factors, biofilm production, and oxidative stress responses [29].
Infections with bacteria from this group are difficult to treat because antibiotic resistance is widespread [4]. Multiple efflux pumps are encoded in most Smc genomes [1,30,31]. These proteinaceous complexes export fluoroquinolones, tetracyclines, trimethoprim, and sulfamethoxazole antibiotics [30–32]. Furthermore, beta-lactamases that inactivate carbapenems are also produced by Smc strains [33]. The prevalence of antibiotic resistance genes varies across Smc lineages [1]. Bacteria from all Smc lineages encode Resistance-Nodulation-Division (RND) efflux pumps, while aminoglycoside-phosphotransferases are found in approximately 60% of all sequenced genomes [1]. K279a possesses two β-lactamase genes: blaL1 and blaL2; while blaL1 is found in more than 80% of Smc genomes, blaL2 is found in less than 65% of genomes and is absent from lineages Sm1, Sm12, Sm13, Sm16, and Sgn4 [1]. Less than 2% of all strains possess the sul1 gene, which confers resistance to sulfonamide [1]. This variation in the prevalence of antibiotic resistance genes among Smc isolates could be explained by the high frequency of horizontal gene transfers proposed to occur among bacteria from this group [1,34].
Strain K279a produces a cell-cell communication molecule called diffusible signal factor (DSF) [35,36]. DSF positively regulates multiple phenotypes associated with pathogenicity, such as production of virulence factors, biofilm, and siderophores [35,36]. DSF also controls antibiotic resistance antibiotics by inducing β-lactamase production [35].
How do Smc isolates interact with other microorganisms?
Smc strains have been recovered from polymicrobial infections that contain bacterial pathogens like Pseudomonas aeruginosa, Staphylococcus aureus, and Escherichia coli [37,38]. Both antagonistic and cooperative interactions have been observed between Smc and other bacteria [37–42]. Using mouse in vivo models, McDaniel and colleagues observed that P. aeruginosa can increase the ability of strain K279a to colonize lungs during co-cultures, suggesting that cooperative interactions exist between these two pathogens during infections [41,42]. Alio and colleagues found that K279a alters gene expression of co-cultured P. aeruginosa and S. aureus and interferes with P. aeruginosa quorum sensing [43]. Furthermore, clinical Smc isolates share mobile genetic elements with P. aeruginosa, suggesting that inter-species horizontal gene transfers occur between these two pathogens [34].
Bacteria from the Smc group also engage in antagonistic interactions, which are dependent on the identities of both attacker and target bacteria [27,38,39,44,45]. Isolates from people with CF display strong antibacterial effects against E. coli but are less successful at eliminating P. aeruginosa or S. aureus [38]. In addition to its roles in degrading eukaryotic proteins, the K279a T4SS can deliver antibacterial proteins that eliminate the plant pathogen Xanthomonas citri, as well as human pathogens like E. coli and P. aeruginosa [27,39,45]. The antibacterial activity of the K279a T4SS is likely dependent on multiple secreted protein effectors, which are neutralized by cognate immunity proteins [39,40,45]. One Smc T4SS effector degrades DNA, while others are predicted to damage the peptidoglycan cell wall or lipid membranes [39,40].
Unlike K279a, Smc strain STEN00241 (which belongs to the sensu lato Sm13 lineage) does not possess T4SS genes, but harbors an antibacterial Type VI Secretion System (T6SS) [44,46]. The T6SS is distinct from the T4SS and adopts a harpoon-like structure [44]. A baseplate and membrane complex span across the bacterial inner membrane, periplasm, and outer membrane to accommodate an inner tube that is decorated with a sharp tip. This inner tube is secreted and delivered along with antibacterial protein effectors into adjacent cells [44]. Similar to the T4SS, immunity proteins neutralize cognate toxins to prevent self-intoxication of bacteria that harbor T6SS effectors. STEN00241 uses the T6SS to eliminate bacterial competitors like E. coli and Burkholderia cenocepacia [44]. Furthermore, the T6SS also modulates interactions between STEN00241 and a co-infecting P. aeruginosa strain isolated from the same patient [44]. T6SS genes encoding multiple putative antibacterial effectors predicted to damage the bacterial cell envelope have been identified in STEN00241 [44].
Another antibacterial weapon used by bacteria to eliminate competitors is contact-dependent inhibition (CDI). CDI systems assemble a membrane pore through which a long, stick-like protein is secreted outside the cell [47]. Once exported, this long protein binds to a receptor on the target cell and delivers an antibacterial toxin. Sibling cells are protected because they express immunity proteins. In general, bacteria can only use CDI toxins to antagonize related cells from the same species or genus. CDI genes and toxins with diverse predicted functions are ubiquitous among Sm6 genomes [47]. A CDI toxin from a CF Sm6 isolate has antibacterial properties and is predicted to degrade tRNA molecules [47]. By contrast, strains from other Smc lineages rarely possess CDI genes, suggesting that this apparatus could have conferred bacteria from the Sm6 lineage competitive advantages over other lineages [47].
Bacteria from the Smc group also engage in interactions with fungi [43, 48]. Candida albicans and Aspergillus fumigatus are opportunistic fungal pathogens that cause infections in people with weakened immune systems due to cancer or its treatment, as well as people with CF, COPD, and those on mechanical ventilation. Sm6 strain ATCC 13637 impairs A. fumigatus hyphal growth, reduces the number of conidia, and causes this fungus to increase its cell wall thickness [48]. Similarly, K279a hinders growth of C. albicans during co-cultures and alters fungal gene expression [43].
In addition to bacteria and fungi, Smc strains interact with bacteriophages (or phages), which are viruses that infect bacterial cells [49,50]. Based on their lifestyle, phages can be either lysogenic or lytic [50]. Following infection, lysogenic phages integrate their genomes onto the bacterial DNA and replicate along with their host. By contrast, lytic phages infect bacteria, reproduce to high numbers, and kill cells to release virus particles that continue the infectious process [49,50]. Lysogenic and lytic phages from diverse viral families that infect Smc strains have been described [49,50]. Furthermore, most Smc isolates harbor genes predicted to encode an extensive arsenal of antiphage defense systems, suggesting that interactions between this bacterium and phages are frequent [51].
Conclusions and future directions
Bacteria from the Smc group are emerging, multidrug-resistant pathogens broadly distributed in natural and anthropogenic environments. These microorganisms possess an array of factors that contribute to their ability to survive in external environments and to cause multiple types of infections. Smc isolates engage in complex interactions with other bacteria, fungi, and phages. Future work is required to understand the regulation of virulence factors and antibiotic resistance genes, the roles played by other microorganisms in modulating Smc pathogenicity, and the potential of alternative options (such as phages) to treat infections resistant to multiple antibiotics.
References
- 1. Gröschel MI, Meehan CJ, Barilar I, Diricks M, Gonzaga A, Steglich M, et al. The phylogenetic landscape and nosocomial spread of the multidrug-resistant opportunist Stenotrophomonas maltophilia. Nat Commun. 2020;11(1):2044. pmid:32341346
- 2. Wang N, Tang C, Wang L. Risk factors for acquired Stenotrophomonas maltophilia pneumonia in intensive care unit: a systematic review and meta-analysis. Front Med (Lausanne). 2022;8:808391. pmid:35096895
- 3. Crossman LC, Gould VC, Dow JM, Vernikos GS, Okazaki A, Sebaihia M, et al. The complete genome, comparative and functional analysis of Stenotrophomonas maltophilia reveals an organism heavily shielded by drug resistance determinants. Genome Biol. 2008;9(4):R74. pmid:18419807
- 4. Langford BJ, So M, Simeonova M, Leung V, Lo J, Kan T, et al. Antimicrobial resistance in patients with COVID-19: a systematic review and meta-analysis. Lancet Microbe. 2023;4(3):e179–91. pmid:36736332
- 5. Kim EJ, Kim YC, Ahn JY, Jeong SJ, Ku NS, Choi JY, et al. Risk factors for mortality in patients with Stenotrophomonas maltophilia bacteremia and clinical impact of quinolone-resistant strains. BMC Infect Dis. 2019;19(1):754. pmid:31462215
- 6. Gunaratnam C, Wilson-Pogmore AA, Weaver T. Stenotrophomonas maltophilia endogenous endophthalmitis in an immunocompetent eye in Australia. BMC Ophthalmol. 2025;25(1):158. pmid:40155838
- 7. Scalia G, Ponzo G, Giuffrida M, Patanè D, Riso MF, Garozzo A, et al. Stenotrophomonas maltophilia-associated odontogenic cerebral abscess in an immunocompetent patient: a case report. Clin Case Rep. 2024;12(7):e9168. pmid:39005575
- 8. Vartivarian SE. Stenotrophomonas (Xanthomonas) maltophilia urinary tract infection. Arch Intern Med. 1996;156(4):433.
- 9. Aisenberg G, Rolston KV, Dickey BF, Kontoyiannis DP, Raad II, Safdar A. Stenotrophomonas maltophilia pneumonia in cancer patients without traditional risk factors for infection, 1997-2004. Eur J Clin Microbiol Infect Dis. 2007;26(1):13–20. pmid:17200840
- 10. Cai B, Tillotson G, Benjumea D, Callahan P, Echols R. The burden of bloodstream infections due to Stenotrophomonas maltophilia in the United States: a large, retrospective database study. Open Forum Infect Dis. 2020;7(5):ofaa141. pmid:32462047
- 11. Waters V, Atenafu EG, Lu A, Yau Y, Tullis E, Ratjen F. Chronic Stenotrophomonas maltophilia infection and mortality or lung transplantation in cystic fibrosis patients. J Cyst Fibros. 2013;12(5):482–6. pmid:23294530
- 12. Rønn C, Kamstrup P, Eklöf J, Toennesen LL, Boel JB, Andersen CO, et al. Mortality and exacerbations associated with Stenotrophomonas maltophilia in chronic obstructive pulmonary disease. A regional cohort study of 22,689 outpatients. Respir Res. 2023;24(1):232. pmid:37752596
- 13. Boktour M, Hanna H, Ansari S, Bahna B, Hachem R, Tarrand J, et al. Central venous catheter and Stenotrophomonas maltophilia bacteremia in cancer patients. Cancer. 2006;106(9):1967–73. pmid:16565968
- 14. Ibn Saied W, Merceron S, Schwebel C, Le Monnier A, Oziel J, Garrouste-Orgeas M, et al. Ventilator-associated pneumonia due to Stenotrophomonas maltophilia: risk factors and outcome. J Infect. 2020;80(3):279–85. pmid:31682878
- 15. AlFonaisan MK, Mubaraki MA, Althawadi SI, Obeid DA, Al-Qahtani AA, Almaghrabi RS, et al. Temporal analysis of prevalence and antibiotic-resistance patterns in Stenotrophomonas maltophilia clinical isolates in a 19-year retrospective study. Sci Rep. 2024;14(1):14459. pmid:38914597
- 16. Banar M, Sattari-Maraji A, Bayatinejad G, Ebrahimi E, Jabalameli L, Beigverdi R, et al. Global prevalence and antibiotic resistance in clinical isolates of Stenotrophomonas maltophilia: a systematic review and meta-analysis. Front Med (Lausanne). 2023;10:1163439. pmid:37215718
- 17. Herring AA, Ginde AA, Fahimi J, Alter HJ, Maselli JH, Espinola JA, et al. Increasing critical care admissions from U.S. Emergency Departments, 2001-2009. Crit Care Med. 2013;41(5):1197–204. pmid:23591207
- 18. Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229–63. pmid:38572751
- 19. Fraser TA, Bell MG, Harris PNA, Bell SC, Bergh H, Nguyen T-K, et al. Quantitative real-time PCR assay for the rapid identification of the intrinsically multidrug-resistant bacterial pathogen Stenotrophomonas maltophilia. Microb Genom. 2019;5(10):e000307. pmid:31617838
- 20. Mojica MF, Humphries R, Lipuma JJ, Mathers AJ, Rao GG, Shelburne SA, et al. Clinical challenges treating Stenotrophomonas maltophilia infections: an update. JAC Antimicrob Resist. 2022;4(3):dlac040. pmid:35529051
- 21. Pompilio A, Piccolomini R, Picciani C, D’Antonio D, Savini V, Di Bonaventura G. Factors associated with adherence to and biofilm formation on polystyrene by Stenotrophomonas maltophilia: the role of cell surface hydrophobicity and motility. FEMS Microbiol. Lett. 2008;287:41–47. https://doi.org/10.1111/j.1574-6968.2008.01292.x pmid:18681866
- 22. Lillehoj EP, Yu Y, Verceles AC, Imamura A, Ishida H, Piepenbrink KH, et al. Stenotrophomonas maltophilia provokes NEU1-mediated release of a flagellin-binding decoy receptor that protects against lethal infection. Sci. 2024;27:110866. https://doi.org/10.1016/j.isci.2024.110866 pmid:39314239
- 23. de Oliveira-Garcia D, Dall’Agnol M, Rosales M, Azzuz ACGS, Alcántara N, Martinez MB, et al. Fimbriae and adherence of Stenotrophomonas maltophilia to epithelial cells and to abiotic surfaces. Cell Microbiol. 2003;5(9):625–36. pmid:12925132
- 24. Karaba SM, White RC, Cianciotto NP. Stenotrophomonas maltophilia encodes a type II protein secretion system that promotes detrimental effects on lung epithelial cells. Infect Immun. 2013;81(9):3210–9. pmid:23774603
- 25. DuMont AL, Karaba SM, Cianciotto NP. Type II secretion-dependent degradative and cytotoxic activities mediated by Stenotrophomonas maltophilia serine proteases StmPr1 and StmPr2. Infect Immun. 2015;83(10):3825–37. pmid:26169274
- 26. DuMont AL, Cianciotto NP. Stenotrophomonas maltophilia serine protease StmPr1 induces matrilysis, anoikis, and protease-activated receptor 2 activation in human lung epithelial cells. Infect Immun. 2017;85(12):e00544-17. pmid:28893914
- 27. Nas MY, White RC, DuMont AL, Lopez AE, Cianciotto NP. Stenotrophomonas maltophilia encodes a VirB/VirD4 type IV secretion system that modulates apoptosis in human cells and promotes competition against heterologous bacteria, including Pseudomonas aeruginosa. Infect Immun. 2019;87(9):e00457-19. pmid:31235638
- 28. Nas MY, Cianciotto NP. Stenotrophomonas maltophilia produces an EntC-dependent catecholate siderophore that is distinct from enterobactin. Microbiology (Reading). 2017;163(11):1590–603. pmid:28984234
- 29. García CA, Alcaraz ES, Franco MA, Passerini de Rossi BN. Iron is a signal for Stenotrophomonas maltophilia biofilm formation, oxidative stress response, OMPs expression, and virulence. Front Microbiol. 2015;6:926. pmid:26388863
- 30. Alonso A, Martinez JL. Expression of multidrug efflux pump SmeDEF by clinical isolates of Stenotrophomonas maltophilia. Antimicrob Agents Chemother. 2001;45(6):1879–81. pmid:11353642
- 31. Lin Y-T, Huang Y-W, Chen S-J, Chang C-W, Yang T-C. The SmeYZ efflux pump of Stenotrophomonas maltophilia contributes to drug resistance, virulence-related characteristics, and virulence in mice. Antimicrob Agents Chemother. 2015;59(7):4067–73. pmid:25918140
- 32. Dulyayangkul P, Calvopiña K, Heesom KJ, Avison MB. Novel mechanisms of efflux-mediated levofloxacin resistance and reduced amikacin susceptibility in Stenotrophomonas maltophilia. Antimicrob Agents Chemother. 2020;65(1):e01284-20. pmid:33139281
- 33. Gould VC, Okazaki A, Avison MB. Beta-lactam resistance and beta-lactamase expression in clinical Stenotrophomonas maltophilia isolates having defined phylogenetic relationships. J Antimicrob Chemother. 2006;57(2):199–203. pmid:16352734
- 34. Mustapha MM, Srinivasa VR, Griffith MP, Cho S-T, Evans DR, Waggle K, et al. Genomic diversity of hospital-acquired infections revealed through prospective whole-genome sequencing-based surveillance. mSystems. 2022;7(3):e0138421. pmid:35695507
- 35. Alcaraz E, García C, Friedman L, de Rossi BP. The rpf/DSF signalling system of Stenotrophomonas maltophilia positively regulates biofilm formation, production of virulence-associated factors and β-lactamase induction. FEMS Microbiol Lett. 2019;366(6):fnz069. pmid:31044250
- 36. An S-Q, Tang J-L. Diffusible signal factor signaling regulates multiple functions in the opportunistic pathogen Stenotrophomonas maltophilia. BMC Res Notes. 2018;11(1):569. pmid:30097057
- 37. Crisan CV, Goldberg JB. Antibacterial contact-dependent proteins secreted by Gram-negative cystic fibrosis respiratory pathogens. Trends Microbiol. 2022;30(10):986–96. pmid:35487848
- 38. Crisan CV, Pettis ML, Goldberg JB. Antibacterial potential of Stenotrophomonas maltophilia complex cystic fibrosis isolates. mSphere. 2024;9(7):e0033524. pmid:38980073
- 39. Nas MY, Gabell J, Cianciotto NP. Effectors of the Stenotrophomonas maltophilia type IV secretion system mediate killing of clinical isolates of Pseudomonas aeruginosa. mBio. 2021;12(3):e0150221. pmid:34182776
- 40. Cobe BL, Dey S, Minasov G, Inniss N, Satchell KJF, Cianciotto NP. Bactericidal effectors of the Stenotrophomonas maltophilia type IV secretion system: functional definition of the nuclease TfdA and structural determination of TfcB. mBio. 2024;15(7):e0119824. pmid:38832773
- 41. McDaniel MS, Schoeb T, Swords WE. Cooperativity between Stenotrophomonas maltophilia and Pseudomonas aeruginosa during polymicrobial airway infections. Infect Immun. 2020;88(4):e00855-19. pmid:31932329
- 42. McDaniel MS, Lindgren NR, Billiot CE, Valladares KN, Sumpter NA, Swords WE. Pseudomonas aeruginosa promotes persistence of Stenotrophomonas maltophilia via increased adherence to depolarized respiratory epithelium. Microbiol Spectr. 2023;11(1):e0384622. pmid:36472421
- 43. Alio I, Moll R, Hoffmann T, Mamat U, Schaible UE, Pappenfort K, et al. Stenotrophomonas maltophilia affects the gene expression profiles of the major pathogens Pseudomonas aeruginosa and Staphylococcus aureus in an in vitro multispecies biofilm model. Microbiol Spectr. 2023;11(6):e0085923. pmid:37819084
- 44. Crisan CV, Van Tyne D, Goldberg JB. The type VI secretion system of the emerging pathogen Stenotrophomonas maltophilia complex has antibacterial properties. mSphere. 2023;8(6):e0058423. pmid:37975665
- 45. Bayer-Santos E, Cenens W, Matsuyama BY, Oka GU, Di Sessa G, Mininel IDV, et al. The opportunistic pathogen Stenotrophomonas maltophilia utilizes a type IV secretion system for interbacterial killing. PLoS Pathog. 2019;15(9):e1007651. pmid:31513674
- 46. Crisan CV, Duncan RP, Van Tyne D, Goldberg JB. Complete genome sequence of Stenotrophomonas maltophilia complex strain STEN00241. Microbiol Resour Announc. 2024;13(2):e0105323. pmid:38132567
- 47. Crisan CV, Goldberg JB. The dominant lineage of an emerging pathogen harbours contact-dependent inhibition systems. Microb Genom. 2025;11(1):001332. pmid:39853206
- 48. Melloul E, Luiggi S, Anaïs L, Arné P, Costa J-M, Fihman V, et al. Characteristics of Aspergillus fumigatus in association with Stenotrophomonas maltophilia in an In Vitro model of mixed biofilm. PLoS One. 2016;11: e0166325. https://doi.org/10.1371/journal.pone.0166325 pmid:27870863
- 49. Monsibais AN, Tea O, Ghatbale P, Dunham SJB, Zünd M, Phan J, et al. Enhanced suppression of Stenotrophomonas maltophilia by a three-phage cocktail: genomic insights and kinetic profiling. Antimicrob Agents Chemother. 2025;69(3):e0116224. pmid:39840957
- 50. García P, Monjardín C, Martín R, Madera C, Soberón N, Garcia E, et al. Isolation of new Stenotrophomonas bacteriophages and genomic characterization of temperate phage S1. Appl Environ Microbiol. 2008;74(24):7552–60. pmid:18952876
- 51. Zhuang Z, Cheng Y-Y, Deng J, Cai Z, Zhong L, Qu J-X, et al. Genomic insights into the phage-defense systems of Stenotrophomonas maltophilia clinical isolates. Microbiol Res. 2024;278:127528. pmid:37918082